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Abstract
Background: Administration of vancomycin in critically ill patients needs close regulation. While subtherapeutical
vancomycin serum concentration (VSC) is associated with increased mortality, accumulation is responsible for
nephrotoxicity. Our study aimed to estimate the efficacy of a vancomycin-dosing protocol in reaching appropriate
serum concentration in patients with and without kidney dysfunction.
Methods: This was a retrospective study in critically ill patients treated with continuous infusion of vancomycin.
Patients with creatinine clearance >50 ml/min (Group A) were compared to those with creatinine clearance
≤50 ml/min (Group B).
Results: 348 patients were enrolled (210 in Group A, 138 in Group B). At first determination, patients with kidney
dysfunction (Group B) had a statistically higher percentage of vancomycin in target range, while the percentage of
patients with a VSC under the range was almost equal. These percentages differed at the subsequent
measurements. The number of patients with low vancomycin concentration progressively decreased, except in
those with augmented renal clearance; the percentage of patients with VSC over 30 mg/L was about 28 %,
irrespective of the presence or absence of kidney dysfunction. Patients who reached a subtherapeutic level at the
first VSC measurement had a significant correlation with in-hospital mortality.
Conclusions: Our protocol seems to allow a rapid achievement of a target VSC particularly in patients with kidney
dysfunction. In order to avoid subtherapeutical VSC, our algorithm should be implemented by the estimation of the
presence of an augmented renal clearance.
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Background
Patients of Intensive Care Units (ICU) are often charac-
terized by a state of immunosuppression induced by
underlying disease, therapies, and impairment of mechan-
ical and immunological protective barriers, which exposes
them to higher risk of hospital-acquired infections. Over
the years, the repeated administration of antibiotic therapy
has favoured the diffusion of Gram-positive Methicillin-
Resistant Staphylococcus Aureus (MRSA), calling for
stronger antibiotic therapies such as vancomycin, which is
currently considered the treatment of choice for most
MRSA infections [1].
Vancomycin, which is a poorly metabolized glycopep-
tide, is mainly excreted unchanged through urine and
has its total body clearance correlated with glomerular
filtration rate [2]. Indeed, creatinine clearance (CrCl) is
frequently used as the clinical surrogate for glomerular
filtration and its measurement can be used in clinical
routines to help dose kidney-excreted drugs, such as
vancomycin [3]. Accumulation of vancomycin may have
major adverse effects such as nephrotoxicity and ototox-
icity, in both patients with and without renal dysfunction
[4]. The incidence of nephrotoxicity can vary between
5 % and 35 % both in patients with and without kidney
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dysfunction [5]; the adverse effects of nephrotoxicity
may include an increase of creatinine, azotemia as well
as changes in urinary sediment (hematuria, proteinuria
and casts). The incidence of ototoxicity ranges between
1 % and 9 % in both patients population [5].
However, more recently, it has been underlined that
antibiotics overdosing could be of less clinical relevance
when compared to underdosing, since the latter is asso-
ciated with an increased mortality [6–9]. Recent studies
suggest that alterations of fluid distribution, hemodynamic
parameters, microcirculation and organ functions may be
associated with subtherapeutic level of vancomycin [4,
8, 10]. The latter is responsible of treatment failure,
selection of resistant organisms and higher mortality
[1, 10–12], underlying that low plasmatic levels of
vancomycin are even more relevant for patient out-
come than increased plasmatic concentration [13].
Furthermore, subtherapeutic levels of vancomycin has
been associated with augmented renal clearance (ARC)
[10], which is characterised by an enhanced renal elimin-
ation of circulating solutes observed in critically ill pa-
tients [6, 9, 12].
Hence, when treating an ICU patient with vancomycin,
physicians should balance accumulation with subthera-
peutic level of vancomycin; though this can be particularly
challenging in patients with kidney dysfunction, as vanco-
mycin clearance is mainly related to kidney function and
such patients are at a higher risk of nephrotoxicity
(compared to those with normal kidney function) [14, 15].
Accordingly, we developed a protocol for vancomycin
infusion that takes into account the clearance of creatin-
ine for determining the daily dose of vancomycin, along
with vancomycin serum concentration (VSC) measure-
ments for the subsequent dose adjustments needed to
overcome the risks of ineffectiveness (failure of treat-
ment) or nephrotoxicity.
The aims of the present study were: (1) to estimate the
efficacy of the vancomycin dosing protocol to reach a
correct serum therapeutic range in critically ill patients
with and without kidney dysfunction (2) to analyse
which factor(s) are related to subtherapeutic VSC.
Methods
This retrospective observational cohort study was per-
formed on clinical records of patients who had been
admitted between March 2010 and July 2013 to a 6-bed
mixed ICU, part of a 740-bed University hospital. The
study was approved by the local Ethics Committee of
Ferrara who waived the need for informed consent in
consideration of the retrospective and observational
nature of the study.
Inclusion criteria were patients having received paren-
tal vancomycin for an empiric or target sepsis treatment
for over 48 hours; whereas exclusion criteria were:
having been treated by Continuous Renal Replacement
Technique, being under 18 years of age, and pregnancy.
Clinical records of evaluated patients were reviewed to
collect information concerning gender, age, weight,
height, SAPS II scores, characteristics of infection, serial
serum creatinine levels and vancomycin dose adminis-
tered by infusion in the 24 h before measurement. CrCl
was obtained daily from 24 h urine collection as a nor-
mal procedure in our ICU and normalised to body sur-
face area, at the beginning and during vancomycin
therapy [10, 13, 16]. The equation for calculating the
CrCl uses the urinary volume, the urinary creatinine
concentration and the serum creatinine concentration.
The presence of an Augmented Renal Clearance was
defined as a CrCl of more than 130 mL/min per 1.73 m2
[10, 12, 13].
In accordance with Maki et al [16], patients were
divided in two groups: those with a creatinine clear-
ance >50 ml/min (Group A), and those with a
creatinine clearance ≤50 ml/min (Group B) [16]. The
flowchart of the study is illustrated in Fig. 1. Data
was coded and downloaded as an electronic file for
further analysis. The presence of concomitant expos-
ure to potential nephrotoxic drugs (including angio-
tensin converting enzyme inhibitors, aminoglycosides,
vasopressor) were also collected [4].
In accordance with data in literature, the routine ICU
vancomycin dosing protocol (Table 1) foresaw administra-
tion by continuous infusion, which is more compatible
with the antibiotic’s pharmacokinetic characteristics.
Throughout the period considered by our study, the
protocol set a weight-based loading dose of 1000 mg for
patients with a body weight <65 Kg, and 1500 mg for pa-
tients with a body weight >65 Kg [5], diluted in a 100 ml
of saline solution and administered over 60 minutes when
the loading dose was 1000 mg; and over 90 min when the
loading dose was 1500 mg. The loading dose was followed
by the infusion of a dose of vancomycin calculated accord-
ing to the CrCl [17]: specifically, 2000 mg/day if creatinine
clearance was >50 ml/min/1,73 m2, 1500 mg/day if
creatinine clearance was between 20–50 ml/min/
1,73 m2, 1000 mg/day if creatinine clearance was
between 10–20 ml/min/1,73 m2 and 500 mg/day if cre-
atinine clearance was < 10 ml/min/1,73 m2. Consecutive
infusion rate was adjusted according to VSC: the daily
dose was increased by 500 mg when VSC was <15 mg/
L, left unchanged when VSC was between 15–25 mg/L,
and was decreased by 500 mg when VSC was >25 mg/L
and the infusion was interrupted for 6 hours when VSC
exceeded 30 mg/L [5, 7] (Table 1).
According to our protocol, blood samples are collected
from the arterial line. Moreover, all the blood samples
for VSC measurements and creatinine were drawn at
7:30 in the morning in all patients receiving vancomycin
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continuous infusion. The first sample of vancomycin
serum concentration of each patient was collected on
the second day after starting the infusion [10], as
suggested by Kitsiz et al [18] who demonstrated that the first
VSC after the LD should be performed within 36–48 hours.
As for our ICU protocol, the subsequent samples were col-
lected every 48 hours. VSC was measured using Dimension®
clinical chemistry system (Dade Behring, Ramsey MN, USA)
with methodology based on immunoassay technique (PETI-
NIA). The VSC laboratory reports were made available in
electronic format to the ICU attending physician in the
afternoon of the same day of blood sample collection. We
considered 15–25 mg/L as the target range of VSC, based
on the assumption that a steady-state 24-h area under the
concentration-time curve divided by the minimum inhibi-
tory concentration ratio (AUC24h/MIC) of ≥400 is associated
with increased clinical success [7]. Vancomycin concentra-
tions were then considered as “insufficient” at <15 mg/L,
“adequate” at 15–25 mg/L, slightly increased at 25–30 mg/L
and “excessive” at >30 mg/L [5, 19]. The safety of the proto-
col was evaluated in terms of nephrotoxicity. The latter was
defined as an increase of 0.5 mg/dl or 50 % increase from
baseline in serum creatinine for two consecutive assays, as
proposed in a recent Consensus Review [5].
Statistical analysis
Statistical analysis was performed by using SPSS 18.0 for
Windows NT (SPSS IncChicago.IL 2004 USA). Because
our data were normally distributed, as evidenced by the
Kolmogorov-Smirnov test, data are presented as means
and standard deviation (SD) or percentage. The statis-
tical analysis was conducted using Chi-square tests or
Fisher’s Exact tests for categorical variables. Multivariate
logistic regression analysis was conducted to assess vari-
ables associated with occurrence of nephrotoxicity. Vari-
ables evaluated in multivariate analysis were vasopressor
(norepinephrine, phenylephrine, or dopamine) infusion,
aminoglycosides, angiotensin converting enzyme inhibi-
tors (ACEi), serum vancomycin and creatinine clearance
at ICU admission. Multivariate logistic regression ana-
lysis was also conducted to assess variables associated
with in-hospital mortality. A p value of <0.05 was con-
sidered to show a statistically significant difference.
Results
The study considered a total of 348 patients. Two hun-
dred and ten had a creatinine clearance >50 ml/min
(Group A) and 138 had a creatinine clearance ≤50 ml/
Fig. 1 Flowchart of the study





< 65 Kg = 1000 mg
if body weight
≥ 65 Kg = 1500 mg
DAILY DOSE:
Creatinine clearance Vancomycin daily dose
>50 ml/min/1,73 m2 2000 mg
50-20 ml/min/1,73 m2 1500 mg
20-10 ml/min/1,73 m2 1000 mg
<10 ml/min/1,73 m2 500 mg
DOSE ADJUSTMENT AFTER VANCOMYCIN SERUM CONCENTRATION
(VSC) MEASUREMENT:
VSC Adjustment dose
<15 mg/L Increase infusion 500 mg/day
15-25 mg/L Do not change infusion
25-30 mg/L Riduce infusion 500 g/day
>30 mg/L Stop infusion for 6 h, than riduced dose
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min (Group B). Demographic and clinical characteristics
of patients are summarized in Table 2.
At the first determination, patients with kidney injury
(Group B) had a statistically higher percentage of VSC
in the target range (Fig. 2), while the percentage of
patients with a VSC under the range was mostly the same.
In this connection it should be pointed out that almost
half of the patients in Group A had an ARC (Fig. 2).
Such percentages differed at the second and third
measurements of VSC. Both groups reduced the number
of patients with a VSC lower than the adequate range,
while the percentage of patients with VSC over 30 mg/L
was about 28 % (Fig. 2), independently from the pres-
ence or absence of kidney dysfunction. The number of
patients with low VSC progressively decreased, except
for those with ARC. Indeed, at the second determin-
ation, 66 % of the patients with VSC below the desired
range had an ARC, while this percentage increased up to
80 % at the third determination. The duration of vanco-
mycin therapy was about 9 days for both groups
(Table 2). Of note, the % of patients with a VSC higher
than 35 mg/dl was extremely low in both groups (Group
A: 0.95 % at the first determination, 1.42 % and 0.95 %
at the second and third determination, respectively.
Group B: 0.72 % at the first determination, 1.44 % at the
second and third determination).
Although the rate of nephrotoxicity was 2,4 % and
9,4 % in Group A and B respectively, no correlations
were found between nephrotoxicity and VSC within the
target range and over the range (p = 0.65). Furthermore
less than 8 % of patients experiencing a VSC >30 mg/L
had a relevant variation of creatinine. Of note, no
nephrotoxicity was observed in presence of a VSC
ranging between 25 and 30 mg/l.
According to the multivariable logistic regression
analysis, nephrotoxicity was not associated with any of
the following variables: vasopressor infusion (p 0.9),
aminoglicosides (p 0.9), angiotensin converting enzyme
inhibitors ace (p 0.9) and serum vancomycin (p 0.7).
The only variable related to nephrotoxicity was the
creatinine clearance at ICU admission (p 0.04). Regard-
ing the possible side effects of vancomycin administra-
tion, we report no ototoxicity in both groups. Finally,
patients who reached a subtherapeutic level at the first
VSC measurement had a significant correlation with in-
hospital mortality (OR 2.1; p 0.003) (Table 3). In this
connection it should be pointed out that the AUC/MIC
in both groups (group A: 468 ± 79 and group B: 490 ±
84, respectively) was in the desired range (>400) [5] at
the first VSC determination (Table 2).
Discussion
The main results of the present study are: 1) our proto-
col seems to consent to a fast achievement of a target
Table 2 Demographic data, patient clinical characteristics, site
of infection and microorganisms identified
GROUP A GROUP B
N. of patients 210 138
Gender male. n. (%) 153 (73) 95 (69)
Age (year) 63.0 ± 11.2 70.6 ± 9.9*
BMI (Kg/m2) 27.2 ± 6.3 26.0 ± 5.6
Basal Serum creatinine (mg/L) 1.0 ± 0.4 2.3 ± 1.4*
Basal Creatinine Clearance
(ml/min/1.73 m2)
106.4 ± 40.7 37 ± 16.2*
Loading dose (mg/kg) 16.7 ± 4.8 18 ± 2
Mean time to first VSC (hours) 40 ± 3 41 ± 2
Total continuous infusion
dosea (g)
5.4 ± 0.3 3.6 ± 0.8*
Duration of vancomycin
therapy (days)
9.0 ± 1.1 9.1 ± 1.6
Nephrotoxicity n. (%) 5 (2.4) 13 (9.4)
Concomitant use of nephrotoxic agents:
Vasopressor n. (%) 32 (15.2) 25 (18.1)
Aminoglycoside. n. (%) 12 (5.7) 9 (6.5)
Ace inhibitor n. (%) 41 (19.5) 21 (15.2)
Type of patient at ICU admission:
Medical n. (%) 119 (56.7) 69 (50.0)
Urgent surgery n. ( %) 7 (3.3) 23 (16.6)*
Scheduled surgery n.(%) 84 (40.0) 46 (33.4)
Admission diagnosis. n. (%)
Sepsis 63 (30 %) 36 (26)
Respiratory failure without sepsis 43 (20.4) 26 (18.8)
Post surgery 80 (38) 66 (47.8)
Other 24 (11.4) 10 (7.2)
SAPS II (first 24 h) 40.3 ± 8.0 46.2 ± 7.7*
ICU deaths. n. (%) 45 (21.4) 33 (23.9)
Site of infection. n.( %)
Low Respiratory Tract 102 (48.6) 50 (36.2)*
Intra-abdominal 43 (20.5) 44 (31.8)*
Bloodstream 30 (14.3) 6 (4.3)*
Skin and soft tissue 23 (10.9) 38 (27.5)*
Other 12 (5.7) 0*
Microorganisms identified. n. (%)
Staphylococci spp 133 (63.3) 86 (62.3)
Enterococci spp 74 (35.2) 52 (37.7)
Streptococci spp 3 ( 1.4) 0
Vancomycin AUC/ MIC at
first determination
468 ± 79 490 ± 84
Continuous variables are reported as mean ± standard deviation (SD); * p<0.05
BMI: Body Mass Index
a Total infusion of vancomycin dose until first determination (included
loading dose)
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VSC in patients with normal kidney function and in
those with kidney dysfunction; 2) the presence of an
augmented renal clearance was the main determinant of
the difficulties in reaching a target VSC.
Early antibiotic administration should aim to reach
adequate target VSC within a few hours from infusion
[10, 17, 19]. However, critically ill patients usually have a
large volume of distribution which likely reflects signifi-
cant capillary leakage. The latter, coupled with aggressive
fluid loading, can expand the interstitial space [4, 20].
Hence hydrophilic antimicrobials — distributed exclu-
sively in the extracellular compartment— are expected
to be diluted. This shift of fluid may favour movement
of drug into the interstitium and a decreased VSC is
expected. Moreover, while critical illness might alter the
volume of distribution, renal dysfunction additionally
makes antibiotic pharmacokinetics even more unpredict-
able [8]. As a consequence, patients with decreased renal
function require vancomycin to be administered follow-
ing dose adjustments. Hence our protocol was designed
in order to avoid both a VSC under and over the target
range, although we choose to favour the avoidance of a
VSC under the range since its association with an in-
creased in-hospital mortality. At the same time we felt
that patients with kidney dysfunction should have had a
specific protocol because of reduced renal clearance.
Finally, target VSC may be difficult to achieve because of
the presence of augmented renal clearance [9, 12, 21].
ARC is characterised by an enhanced renal elimination of
circulating solutes observed in critically ill patients [8, 22].
The presence of ARC might imply subtherapeutic levels of
a given drug for substantial periods of the dosing interval
resulting in treatment failure or selection of resistant
organisms [1, 12, 22].
All the above mentioned factors imply great inter-
individual variability in pharmacokinetics, complicating
accurate prediction of serum concentrations in ICU
patients, making evident the need of a frequent dosage
of VSC in order to make the daily dose of this antibiotics
adequate [5].
A below-range VSC was observed in only 20 % of
patients of both groups. However, only patients with
kidney dysfunction progressively and significantly re-
duced this percentage, which became about 9 % at the
third VSC determination. Interestingly, the group with
normal kidney function had a different behaviour.
Between the first and the third VSC determination, it
became progressively evident the relevance of an ARC
that did not allow this group to decrease the percent-
age of patients with VSC under the range. This is of
clinical relevance since patients who reached a sub-
therapeutic level at the first VSC measurement had a
significant correlation with in-hospital mortality (OR
2.1; p 0.003).
Fig. 2 Distibution of vancomycin concentration in patients with and without nephrotoxicity. All Statistically significant p-value (<0.05) are marked
in the figure. # p = 0,026; + p = 0,005; § = 0,024; o p < 0,001; *p = 0,005
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As to the VSC in the desired range, only at the first
determination group B had higher percentage of patients
with VSC in the normal range and, as a consequence, a
lower percentage with a VSC over the range (Fig. 2). At
the second and the third VSC determination the two
groups were almost identical. This was the case also for
VSC over the target range, being the percentage of
patients with a VSC higher than 30 mg/L of about 28 %.
The increase of VSC over the target range has been
associated with a risk of nephrotoxicity that has a
reported incidence up to 35 % during vancomycin ther-
apy [23, 24]. Hence we investigated the effects of VSC
over the target range on renal function. Interestingly no
correlation was found between VSC and renal toxicity,
even in patients with kidney dysfunction. This is relevant
from the clinical point of view, since other and more
expensive antibiotics are usually proposed in patients at
risk of kidney dysfunction. Such result can be explained
by several factors. First of all, we considered 15–25 mg/L
as a target range since a VSC over 25 mg/L can be
associated with increase of nephrotoxicity, as previously
described [6]. However, other studies have proposed an
upper limit of 30 mg/L [12], suggesting that nephrotox-
icity could be enhanced when the VSC reaches values
higher than 30 mg/L, as it was the case of the present
study. The VSC > 30 mg/L was found in about 30 % of the
patients of both groups (Fig. 2), whilst the % of patients
with a VSC higher than 35 mg/dl was extremely low in
both groups (about 1 %, see results section). These results
underline that our algorithm is able to adjust the VSC
preventing the progressive accumulation of vancomycin
without incurring the opposite phenomenon, that is a
VSC below 15 mg/dl.
Our algorithm is based on a continuous infusion of
vancomycin that might have advantages over intermittent
administration [25, 26] since this strategy appears to re-
duce renal toxicity [25]. Despite previous studies compar-
ing continuous and intermittent administration have
reached conflicting results [27], others demonstrated that
continuous infusion of vancomycin is less expensive and
quicker in achieving target concentration, resulting in less
variability in serum concentrations [27, 19].
The presence of patients with a VSC > 30 mg/L implies
that our algorithm should not be changed by increasing
the daily dose of vancomycin in order to avoid a VSC
under the desired range. This is suggested by the AUC/
MIC ratio, which was even at the first VSC determin-
ation much higher than 400 (Table 2). This is of clinical
relevance since Holmes et al [28] have previously dem-
onstrated a 12 % lower mortality 30-day mortality in
patients achieving a vancomycin AUC/MIC of >373
within the first 96 h of vancomycin therapy compared to
those who did not. Instead, we believe that our algo-
rithm should take into account the presence of ARC,
therefor increasing the dose only in patients that really
need this adjustment of the therapy.
Limitation of the study
We used a loading dose of about 15 ml/Kg of actual
body weight to avoid too high VSC. However, the LD
varies among different studies and other authors suggest
a LD of about 25–30 mg/Kg (low level of evidence – III
- and grade of recommendation B) [5], with the aim of
rapid achievement of the target VSC. Looking at our
data, between 40 and 50 % of patients of both groups
were over-range, generating a clinical dilemma. Should
we modify our algorithm by increasing the loading dose
or should we maintain the LD used in the present study?
Indeed, it can be hypothesized that higher LD would
have determined higher plasmatic concentration. Hence
it could be expected an increased % of patient in over-
range or even of patients in over range with VSC much
higher than those obtained in the present study, leading
to an increase of nephrotoxicity. Moreover, the AUC/
MIC was much higher than 400 for both groups Table 2),
suggesting that the LD might have been sufficient to
reach the expected VSC. Further studies are required to
clarify if an increased LD could decrease the % of pa-
tients in under-range without increasing nephrotoxicity.
Finally, calculation of creatinine clearance implies deter-
mination of urinary creatinine. The latter, however is influ-
enced by the volume status of the patient, treatment with
the loops diuretics and vasopressor agents, and release of
antidiuretic hormone. Indeed, correct estimation of glom-
erular filtration rates implies its determination by using inu-
lin or iohexol clearance, and radionucleotide. Unfortunately,
these methods are largely unavailable in the clinical setting.
Conclusions
Our protocol seems to allow a rapid achievement of a target
VSC particularly in patients with kidney dysfunction. In
order to avoid subtherapeutic VSC, our algorithm should
be implemented by the estimation of ARC, the presence of
which implies an adjustment of the dose of vancomicyn,
both in terms of loading and continuous infusion dose.
Table 3 Variable associated with in hospital mortality
(multivariate analysis)
Variables Odds Ratio 95 % CI p value
VSC under range at
first determination
2.147 1.953 – 2.350 0.003a
SAPS II 1.038 1.019 – 1.058 0.003a
Age 1.017 997 – 1.037 0.396
BMI 0.957 0.913 – 1.003 0.08
Creatinine clearance 0.990 0.984 - 0.996 0.832
aSignificance with p-value < 0.05
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